Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05885412 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
A Phase 1 study of PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), sponsored by Rocket Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 3
- Study locations
NCT05885412: Recruiting Phase 1 study of PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), sponsored by Rocket Pharmaceuticals.
NCT05885412 is a Phase 1 study of PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) that is actively recruiting participants, run by Rocket Pharmaceuticals. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05885412, a Phase 1 study of PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), is actively recruiting participants, sponsored by Rocket Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 3
- Study locations
Study Summary
This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.
Primary Outcome
Incidence of treatment emergent adverse events (TEAEs), incidence of Serious Adverse Events (SAEs), and identification of Dose Limiting Toxicities (DLTs)
Conditions Studied
Interventions
- GENETIC RP-A601
Study Locations (3)
California
- University of California, San Diego - La Jolla
North Carolina
- Duke University - Durham
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-08-29 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
What NCT05885412 shows while recruiting
NCT05885412 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) appearing as the primary indexed condition, and to 1 intervention - of which RP-A601 is the first listed.
NCT05885412 reports a single indexed study location in California, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05885412 about?
NCT05885412 is a clinical study titled "A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)". This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.
What is the current status of trial NCT05885412?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-08-29. Estimated completion is 2026-09.
What conditions does trial NCT05885412 study?
This clinical trial studies the following conditions: PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM).
What interventions are being tested in trial NCT05885412?
The interventions under investigation include: RP-A601 (GENETIC).
Who is sponsoring clinical trial NCT05885412?
This trial is sponsored by Rocket Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05885412 being conducted?
This trial has 3 study locations across California, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05885412's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI